Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Séverine Vermeire, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2018Cited by 158
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Marc Ferrante, Erwin Dreesen et al.|Journal of Crohn s and Colitis|2019Cited by 123
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD PatientsBram Verstockt, Marc Ferrante, Maja Noman et al.|Journal of Crohn s and Colitis|2019Cited by 38
Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's diseaseZhigang Wang, Erwin Dreesen, Bram Verstockt et al.|British Journal of Clinical Pharmacology|2021Cited by 32
Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation StudyZhigang Wang, Erwin Dreesen, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2023Cited by 21